Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 493

1.

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.

Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN.

Am J Clin Oncol. 2008 Feb;31(1):49-54. doi: 10.1097/COC.0b013e3180684181.

PMID:
18376228
2.

Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.

Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S.

J Surg Oncol. 2003 Jul;83(3):147-53.

PMID:
12827682
3.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
4.

Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).

Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL.

Ann Surg Oncol. 1999 Sep;6(6):582-90.

PMID:
10493628
5.

[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].

Gómez Portilla A, Cendoya I, Muriel J, Olabarria I, Guede N, Moraza N, Fernández E, Martínez de Lecea C, Magrach L, Martín E, Romero E, Aguado I, Valdovinos M, Larrabide I.

Cir Esp. 2007 Feb;81(2):82-6. Spanish.

6.

Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR.

J Clin Oncol. 2003 Dec 15;21(24):4560-7.

PMID:
14673042
7.

Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.

Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O.

Ann Surg Oncol. 2006 Mar;13(3):405-12. Epub 2006 Jan 30.

PMID:
16485159
8.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID:
17661150
9.

Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S.

Ann Surg Oncol. 2006 Feb;13(2):229-37. Epub 2006 Jan 18.

PMID:
16444562
10.

Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.

Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J.

Anticancer Res. 1999 May-Jun;19(3B):2317-21.

PMID:
10472351
12.

Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M.

Eur J Surg Oncol. 2010 Nov;36(11):1047-53. doi: 10.1016/j.ejso.2010.08.130. Epub 2010 Sep 15.

PMID:
20832234
13.

8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H.

Ann Surg Oncol. 2008 Sep;15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3.

PMID:
18521686
14.

Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.

Lee TT, Everett DL, Shu HK, Jahan TM, Roach M 3rd, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM.

J Thorac Cardiovasc Surg. 2002 Dec;124(6):1183-9.

15.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

16.

Peritoneal mesothelioma.

Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M.

Curr Treat Options Oncol. 2000 Oct;1(4):303-12. Review.

PMID:
12057156
17.
18.

Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M.

Eur J Cancer. 2013 Oct;49(15):3140-8. doi: 10.1016/j.ejca.2013.05.027. Epub 2013 Jul 4.

PMID:
23831335
19.
20.

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.

Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR.

Cancer J Sci Am. 1997 May-Jun;3(3):174-9.

PMID:
9161783

Supplemental Content

Support Center